Next Generation Humanized Mice for AML and NK Cell Therapy Testing

Logo
Presented by

Amy Wesa, PhD, Director of Immuno-Oncology Research at Champions Oncology

About this talk

To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to enable predictive outcomes. Patient-derived models represent a considerable advantage over traditional models of cancer to expedite drug development. In this webinar, Amy Wesa, PhD, of Champions Oncology Inc, will discuss how complementing these translational PDX models with the introduction of human immune cells is driving the next generation of patient-derived models. View this webinar to learn: The latest advances in human immune system mouse models for oncology therapeutics The power of primary patient-derived models for acute myeloid leukemia (AML) Novel methods for evaluating natural killer (NK) cell therapeutics of cancer in humanized mice
Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (56)
Subscribers (3271)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.